Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 6/20 | 0.39 |
| ▸ | MLYCD | O95822 | 5/20 | 0.37 |
| ▸ | GCGR | P47871 | 2/20 | 0.36 |
| ▸ | GIPR | P48546 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 1/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1947508 | 0.86 | KMT2A (0.36) | MLYCD | |
| SCHEMBL1438386 | 0.85 | MLYCD (0.44) | SERPINE1MLYCD | |
| SCHEMBL1946884 | 0.85 | MLYCD (0.38) | MLYCD | |
| SCHEMBL1949171 | 0.84 | SMN1; SMN2 (0.36) | MLYCD | |
| SCHEMBL1950136 | 0.83 | MLYCD (0.40) | MLYCD | |
| SCHEMBL1950111 | 0.83 | MLYCD (0.35) | MLYCD | |
| SCHEMBL6519394 | 0.79 | SERPINE1 (0.44) | SERPINE1GCGRGIPREPHX1CETP | |
| SCHEMBL1949099 | 0.78 | SERPINE1 (0.38) | SERPINE1MLYCDGCGRGIPREPHX1 | |
| SCHEMBL6526993 | 0.77 | SERPINE1 (0.40) | SERPINE1MLYCDGCGRGIPREPHX1 | |
| SCHEMBL2483257 | 0.75 | SERPINE1 (0.38) | SERPINE1MLYCDEPHX1GPR88TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | SERPINE1 11/4885MLYCD 3443/4885GCGR 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.